期刊文献+

HPLC法检查苯甲酸阿格列汀原料药的有关物质 被引量:6

Determination of Related Substances in Alogliptin Benzoate Raw Materials by HPLC
原文传递
导出
摘要 目的:建立检查苯甲酸阿格列汀原料药中有关物质的方法。方法:采用高效液相色谱梯度洗脱法。色谱柱为C18,流动相A为0.2%磷酸溶液(pH 3.0),流动相B为乙腈,以1.0 ml/min流速进行梯度洗脱,检测波长为225 nm,进样量为20μl。采用不加校正因子主成分自身对照法检查特定杂质F-1的量。结果:苯甲酸阿格列汀与F-1及其他未知杂质均分离良好,前二者检查质量浓度线性范围分别为0.187 2~0.748 8、0.184 5~0.738 0μg/ml(r=0.999 7、0.999 9);F-1的检测限和定量限分别为2.5、7.5 ng,平均回收率为100.9%(RSD=1.10%,n=3);3批样品中F-1量均≤0.06%。结论:建立的方法灵敏快速、结果准确可靠,可作为苯甲酸阿格列汀原料药的有关物质检查方法。 OBJECTIVE: To establish a method for the determination of related substances in Alogliptin benzoate (AB) raw materials. METHODS: HPLC-gradient elutior method was adopted. The determination was performed on C18 column with mobile phase A consisted of 0.2% phosphoric acid solution (pH adjusted to 3.0) and mobile phase B consisted of acetonitrile at the flow rate of 1.0 ml/min (gradient elution). The detection wavelength was set at 225 nm and sample size was 20 μl. The content of impu- rity F-1 was determined by the self-control method without correction factor. RESULTS: AB, F-1 and other impurities were completely separated. The linear range was 0.187 2-0.748 8 μg/ml for AB and 0.184 5-0.738 0 μg/ml for F-1 (r=0.999 7, 0.999 9). The limits of detection and quantification were 2.5 ng and 7.5 ng for F-1. The average recovery was 100.9% (RSD=1.10%, n= 3); the content of F-1 in 3 batches of samples were ≤0.06%. CONCLUSIONS: The method is sensitive, rapid, accurate and reliable, and can be used for the determination of related substance in AB raw materials.
出处 《中国药房》 CAS CSCD 2014年第33期3141-3143,共3页 China Pharmacy
关键词 苯甲酸阿格列汀 高效液相色谱法 梯度洗脱 有关物质 Alogliptin benzoate HPLC Gradient elution Related substances
  • 相关文献

参考文献5

二级参考文献26

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2Green BD, Flan PR, Bailey Cj. Dipeptidyl peptidase Ⅳ ( DPP Ⅳ) inhibitors:A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006,3 ( 3 ) : 159.
  • 3Rosenstock J, Brazg R, Andryuk PJ. Efficacy and safety of the dipeptidyl peptidase -4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes : a 24 - week, multicenter, randomized, double - blind, placebo - controlled, parallel - group study. Clin Ther. 2006,28 (10) : 1556.
  • 4Sitagliptin with metformin : profile of a combination for the treatment of type 2 diabetes. Drugs Today(Barc). 2007,43 (10) :681.
  • 5Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008,24(2) :537.
  • 6Mistry GC, Bergman A J, Luo WL, et al. Multiple -dose administration of sitagliptin, a dipeptidyl peptidase - 4 inhibitor, does not alter the single - dose pharmacokinetics of rosiglitazone in healthy subjects. Diabetes Obes Metab. 2007,47 ( 2 ) : 159.
  • 7Brazg R, Xu L, Dalla man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase- 4 inhibitor, to metformin on 24 -h glycemic control and beta - cell function in patients with type 2 diabetes. Rapid Commun Mass Spectrom. 2007,9 (2) :186.
  • 8Wei Zeng, Donald G Musson, Alison L Fisher, et al. Determination of MK -0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006,20 ( 8 ) : 1169.
  • 9Ramakrisboa Nirogi, Vishwottam Kandikere, Koteshwara Mudigonda,et al. Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP - 4 inhibitor, in human plasma using liquid - liquid extraction. Biomed Chromatogr. 2007,22(2) :214.
  • 10Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase Ⅳ, in healthy subjects : results from two randomized, double - blind, placebo- controlled studies with single oral doses. Clin Pharmacol Ther. 2005,78 (6) :675.

共引文献30

同被引文献32

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部